EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany

Ria Heinrich, Franziska Claus, Tonio Schoenfelder iD

Orphanet Journal of Rare Diseases · 2024

DOI: 10.1186/s13023-024-03492-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Orphanet Journal of Rare Diseases, 2024. Verfasst von Ria Heinrich und 2 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Institute of Health Economics and Health System Research (WIG2 GmbH), Leipzig, Germany. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Lysosomal Storage Diseases, Health Care Costs, Home Care Services. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi-Aventis Deutschland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lysosomal storage diseases (LSDs) can be treated with intravenous enzyme replacement therapy (ERT). ERT is being administered either in specialized clinics or in the home care setting. Studies indicate that home-based ERT can be considered safe and positively effects patient reported outcomes. Due to the higher level of individual care required by nurses when administering ERT at home, questions arise whether this will result in additional costs for health care systems. Since cost data to the German health care system are currently unavailable, this study aims to assess home care ERT costs of LSD patients.

Methods

The longitudinal study assessed the direct costs of home-based ERT for patients with LSD diseases Fabry, Pompe, Gaucher, and MPS I from 2019 to 2021 on a patient-by-patient basis by evaluating the healthcare documentation. Costs assessed included ERT drug and further administration equipment, time needed to prepare, administer, and post-process the infusion, and travel expenses of nursing staff.

Results

Data from 62 patients was analyzed: of these, 29 (46.8%) with Fabry disease, 19 (30.6%) with Pompe disease, 10 (16.1%) with Gaucher disease, and 4 (6.5%) with MPS I. Patients ranged in age from 3 to 79 (mean 40 years); 42% of patients reported comorbidities (19.4% with hypertension, and 10% with heart disease). Mean total ERT-related costs were €369,047 per year across all patients. Approximately 98.5% of these costs were attributable to the infusion therapy and administration itself (€363,880), and approximately 1.5% were attributable to personnel and travel costs. Patients with Pompe disease incurred the highest average annual costs (€483,907) and patients with Fabry disease the lowest (€264,896). Cost differences among underlying LSDs were due primarily to ERT drug costs; the drug infused for Fabry disease costs about half as much as that for Gaucher or for Pompe disease. Despite MPS I patients requiring about twice as many infusions, significantly lower drug costs for this disease resulted in the second lowest total mean costs of all LSD subtypes analyzed.

Conclusion

As total costs are almost entirely driven by infusion-related material, especially the ERT drug, moving ERT into the home environment is not expected to increase costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme Replacement TherapyLysosomal Storage DiseasesHealth Care CostsHome Care ServicesHumansGermanyMaleFemaleAdultAdolescentYoung AdultChildMiddle AgedLongitudinal StudiesChild, PreschoolFabry DiseaseAged

Stichwörter der Autor:innen

Cost analysisEnzyme replacement therapyFabry diseaseGaucher diseaseGermanyHome care therapyHome infusionLysosomal storage diseaseMPS IMucopoly-saccharidosis type IPompe disease

Autor:innen und Institutionen

  • Scientific Institute of Health Economics and Health System Research (WIG2 GmbH), Leipzig, Germany.
  • Scientific Institute of Health Economics and Health System Research (WIG2 GmbH), Leipzig, Germany. tonio.schoenfelder@wig2.de.
  • Chair Health Sciences-Public Health, Technische Universität Dresden, Dresden, Germany. tonio.schoenfelder@wig2.de.

ORCID-Profile: Tonio Schoenfelder

Förderung

  • Sanofi-Aventis Deutschland

Zitieren

APA

Heinrich, R., Claus, F., & Schoenfelder, T. (2024). Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-024-03492-4

Vancouver

Heinrich R, Claus F, Schoenfelder T. Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany. Orphanet Journal of Rare Diseases. 2024. doi:10.1186/s13023-024-03492-4

BibTeX
@article{Heinrich2024,
  author = {Heinrich, Ria and Claus, Franziska and Schoenfelder, Tonio},
  title = {Health care costs of home care enzyme replacement therapy for patients with lysosomal storage diseases in Germany},
  journal = {Orphanet Journal of Rare Diseases},
  year = {2024},
  doi = {10.1186/s13023-024-03492-4}
}
Kostenlos starten →